Assignee
RESPIVERT LTD
GB52 patents
Top patents by PatentIndex Score
US8927563B2Jan 6, 2015
Kinase inhibitor
RESPIVERT LTD39 citations98
US9108950B2Aug 18, 2015
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors
RESPIVERT LTD38 citations96
US9624196B2Apr 18, 2017
Inhibitor of p38 MAP kinase
RESPIVERT LTD15 citations92
US9499486B2Nov 22, 2016
Kinase inhibitor
RESPIVERT LTD14 citations92
US9475796B2Oct 25, 2016
1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
RESPIVERT LTD12 citations92
US9447076B2Sep 20, 2016
Inhibitor of p38 map kinase
RESPIVERT LTD16 citations92
US8975285B2Mar 10, 2015
P38 MAP kinase inhibitors
RESPIVERT LTD26 citations92
US9249125B2Feb 2, 2016
Pyrazole derivatives as p38 MAP inhibitors
RESPIVERT LTD30 citations91
US9481648B2Nov 1, 2016
Kinase inhibitors
RESPIVERT LTD22 citations90
US9822076B2Nov 21, 2017
Kinase inhibitor
RESPIVERT LTD3 citations84
US9724347B2Aug 8, 2017
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors
RESPIVERT LTD5 citations84
US10125100B2Nov 13, 2018
Kinase inhibitors
RESPIVERT LTD6 citations83
US9751837B2Sep 5, 2017
Kinase inhibitors
RESPIVERT LTD6 citations83
US9242960B2Jan 26, 2016
P38MAP kinase inhibitors
RESPIVERT LTD6 citations83
US10266519B2Apr 23, 2019
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors
RESPIVERT LTD6 citations82
US9890185B2Feb 13, 2018
Urea derivatives useful as kinase inhibitors
RESPIVERT LTD8 citations82
US9850231B2Dec 26, 2017
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors
RESPIVERT LTD5 citations82
US9701670B2Jul 11, 2017
Pyrazolyl-ureas as kinase inhibitors
RESPIVERT LTD10 citations80
US10238658B2Mar 26, 2019
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
RESPIVERT LTD3 citations73
US9993478B2Jun 12, 2018
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
RESPIVERT LTD2 citations73
US9771353B2Sep 26, 2017
Kinase inhibitors based upon N-alkyl pyrazoles
RESPIVERT LTD3 citations73
US10294216B2May 21, 2019
Pyrazolyl ureas as kinase inhibitors
RESPIVERT LTD1 citations72
US10072034B2Sep 11, 2018
Kinase inhibitors
RESPIVERT LTD3 citations72
US9790174B2Oct 17, 2017
Kinase inhibitors
RESPIVERT LTD3 citations72
US10738032B2Aug 11, 2020
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors
RESPIVERT LTD3 citations71
US9227977B2Jan 5, 2016
Phosphoinositide 3-kinase inhibitors
RESPIVERT LTD4 citations71
US11208381B2Dec 28, 2021
Indole derivatives and their use as protein kinase inhibitors
RESPIVERT LTD2 citations70
US10669235B2Jun 2, 2020
Indole derivatives and their use as protein kinase inhibitors
RESPIVERT LTD2 citations70
US11634406B2Apr 25, 2023
Inhibitor of p38 MAP kinase
RESPIVERT LTD0 citations62
US9796742B2Oct 24, 2017
Kinase inhibitors
RESPIVERT LTD2 citations62
US9340545B2May 17, 2016
Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitors
RESPIVERT LTD1 citations62
US9321773B2Apr 26, 2016
Compounds
RESPIVERT LTD2 citations62
US11142515B2Oct 12, 2021
Pyrazolyl-ureas as kinase inhibitors
RESPIVERT LTD0 citations61
US10358445B2Jul 23, 2019
Respiratory formulations and compounds for use therein
RESPIVERT LTD1 citations61
US9884845B2Feb 6, 2018
Pyrazolyl-ureas as kinase inhibitors
RESPIVERT LTD1 citations61
US10813932B2Oct 27, 2020
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
RESPIVERT LTD0 citations52
US9850233B2Dec 26, 2017
Kinase inhibitors
RESPIVERT LTD0 citations52
US10815217B2Oct 27, 2020
Inhibitor of p38 MAP kinase
RESPIVERT LTD0 citations51
US10045980B2Aug 14, 2018
Inhibitor of p38 map kinase
RESPIVERT LTD0 citations51
US10028959B2Jul 24, 2018
Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors
RESPIVERT LTD0 citations51
US10000471B2Jun 19, 2018
Pyrazole P38 map kinase inhibitors
RESPIVERT LTD0 citations51
US9834560B2Dec 5, 2017
Compounds
RESPIVERT LTD1 citations51
US9771354B2Sep 26, 2017
Pyrazole p38 map kinase inhibitors
RESPIVERT LTD1 citations51
US9637494B2May 2, 2017
Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors
RESPIVERT LTD0 citations51
US10144721B2Dec 4, 2018
P38 MAP kinase inhibitors
RESPIVERT LTD0 citations50
US9745306B2Aug 29, 2017
2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
RESPIVERT LTD0 citations50
US9556184B2Jan 31, 2017
Phosphoinositide 3-kinase inhibitors
RESPIVERT LTD0 citations50
US11046672B2Jun 29, 2021
Indolinones compounds and their use in the treatment of fibrotic diseases
RESPIVERT LTD0 citations46
US9642799B2May 9, 2017
Crystalline 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-0X0-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide
RESPIVERT LTD1 citations45
US9783556B2Oct 10, 2017
Kinase inhibitors
RESPIVERT LTD0 citations41
Showing the top 50 of 52 patents by PatentIndex Score.